Navigation Links
Solos Endoscopy, Inc. Increases Sales Revenue for October 2008 by Over 10% as Compared to Last Year
Date:12/10/2008

BOSTON, Dec. 10 /PRNewswire-FirstCall/ -- Solos Endoscopy, Inc. (OTC Pink Sheets: SNDY) is pleased to announce that the Company increased sales revenue for the month of October 2008 by over 10% compared to the same time period for 2007. Revenues generated during October 2008 reached $ 31,508 as compared with $28,509 for the same month last year. This marks the second consecutive year that the Company's revenue has increased for the month of October.

The Mammo View(TM) system has expanded Solos' product line to reach a broader vertical market. The Company has received numerous purchase orders, and shipping systems to hospitals around the U.S. The Mammo View(TM) system contains versatile and customizable medical equipment that can support multiple procedures including biopsies, lumpectomies, and other intraductal procedures. The Mammo View(TM) has the potential to help the early diagnosis of more than 1 million cases of breast cancer discovered each year throughout the world.

"October is typically a slow month for our surgical sales, however, this year we have continued to grow our October sales revenue. We believe our Mammo View (TM) line will continue to improve our profitability and will have a highly positive effect on the Company's financials within the coming New Year," stated Bob Segersten, President of Solos Endoscopy, Inc.

About Solos Endoscopy, Inc.:

Solos Endoscopy, Inc. is a healthcare technology company whose mission is to develop and market breakthrough technology, applications, medical devices, and procedural techniques for the screening, diagnosis, treatment and management of medical conditions. Backed by technical support, Solos' sales team can help make the right buying decisions for the hospital, surgery center, or physician office. Additional information is available on the Company's website at: www.solosendoscopy.com.

Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.


'/>"/>
SOURCE Solos Endoscopy, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Solos Endoscopy, Inc.s Mammo View(TM) System Now Used in Womens Hospital of Baton Rouge, LA
2. Solos Endoscopy, Inc. Posts First Six Months Financials of 2008 on Pinksheets.com
3. Bio-Imaging Technologies Partners with AG Mednet to Offer Complete Imaging Solution for Clinical Trials : --Partnership Increases Trial Efficiency and Enhances Data Quality--
4. Hillenbrand, Inc. Increases Quarterly Dividend to $0.185 Per Share
5. USAID Increases Assistance for Zimbabwe Cholera Outbreak
6. Cancer Mortality Increases With Cancer Cell Replikin Count
7. Stryker Increases Annual Dividend by Over 20%
8. Portable CT increases chance of stroke survival and recovery
9. Dual-head gamma camera increases ability to detect breast tumors not seen on mammography
10. Landauer, Inc. Increases Regular Cash Dividend and Declares First Quarter Payment
11. Panel Demands FDA Action to Address Dramatic Increases in Skin Cancer in U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... ... April 25, 2017 , ... Back Pain Centers ... back pain with a reputable physician in their area, announces the launch of a ... information for patients who are looking for reputable physicians to help them with back ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... ... addition of predictive analytics to its patient care management module. Using this new ... before a patient has been initiated on continuous positive airway pressure (CPAP), oral, ...
(Date:4/25/2017)... ... April 25, 2017 , ... Vetoquinol USA® ... introducing Flexadin UCII, part of the EQUISTRO line, at this week’s Rolex Kentucky ... horses at the immunologic level. , The scientifically-developed Flexadin UCII supports the body’s ...
(Date:4/24/2017)... ... April 24, 2017 , ... LG ... Your Own Device (BYOD) capabilities at Telehealth 2.0, the American Telemedicine Association’s national ... which pairs medical devices with a pre-programmed tablet in a remarkably easy-to-use kit ...
(Date:4/24/2017)... ... 2017 , ... Ridgecrest Herbals makes it a point to lead the Utah ... and support renewable energy. They believe this is a crucial part of their mission ... health issues, and maintain that destroying the environment in the pursuit of profit is ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today ... C virus (HCV) infected patients with genotype 1, ... (Child-Pugh A) achieved sustained virologic response at 12 ... pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These high SVR ... of G/P treatment without ribavirin. Patients with specific ...
(Date:4/20/2017)... Sweden , April 20, 2017 ... NEVPF) ("NeuroVive") today announced positive preclinical results ... preclinical compound for non-alcoholic steatohepatitis (NASH), in ... NV556 has previously shown ... NASH model. Today, NeuroVive,s scientists present novel ...
(Date:4/19/2017)... NEW YORK , April 19, 2017 Cardiology ... during the projected period The Cardiology Devices segment ... more than US$ 15 Mn in 2018 over 2017. By ... reach a market valuation close to US$ 700 Mn, expanding ... Cardiology Devices segment dominated the Asia Pacific ...
Breaking Medicine Technology: